September 10, 2007 - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders, announced the successful completion of a Phase 2a safety trial with TPI 1020 in smokers with asthma.TOPIGEN also announced plans to initiate a Phase 2 clinical trial of TPI 1020 in chronic obstructive pulmonary disease (COPD) in the second half of 2007.TPI 1020 is a novel anti-inflammatory respiratory drug licensed from NicOx S.A.
TOPIGEN Pharmaceuticals' Press Release -
